In Out-Licensing Agreements

We are actively seeking out licensing agreements and strategic partnerships with international pharmaceutical companies that focus on the commercialization of generic drugs in order to develop new segments and expand into these markets. Licensing out has become an essential part of the business strategies of most biotech companies. Nevertheless, several recent research reports show that biotechnology companies are better able to measure in the current licensing environment. The reports argue that biotechnology companies are not maximizing the value of their assets because of inefficient offline licensing processes. To increase shareholder value, biotech companies that want one or more of their programs must do one of two things. They must either engage in a dedicated internal licensing team, with a best practice process, out-of-competition licensing and an infrastructure capable of presenting their technology in a methodical and proactive manner, or consider recruiting professional support from a company capable of providing its proven knowledge, experience, networks and processes, so that management remains fully engaged and focused on its core operational activities. Abandoning a thorough prioritization process, which eliminates less relevant businesses and only targets strategic partners and individuals within target companies, can speed up the licensing process. Many companies fail to tailor the information sent to partners based on their synergistic search results and therefore have no early benefit to the partner, which greatly reduces the likelihood of a first screening. Marksans is engaged in the development of new drugs and has entered into licensing agreements with other global pharmaceutical groups. Just as pharmaceutical companies are always looking for the next drug to blockbuster, investors are looking for the company that will develop it. For this reason, licensing agreements can be a bit repugnant – even if a drug is extremely effective, its benefits must be split between two pharmaceutical companies and therefore two groups of shareholders.